Pacific Therapeutics Pharmafirma aus Kanada - 500 Beiträge pro Seite
eröffnet am 23.10.13 11:39:41 von
neuester Beitrag 24.07.15 11:30:38 von
neuester Beitrag 24.07.15 11:30:38 von
Beiträge: 28
ID: 1.187.537
ID: 1.187.537
Aufrufe heute: 0
Gesamt: 13.000
Gesamt: 13.000
Aktive User: 0
ISIN: CA89186Q1019 · WKN: A2DKQ4 · Symbol: TO
0,0900
CAD
+80,00 %
+0,0400 CAD
Letzter Kurs 22.02.24 CSE
Neuigkeiten
10.11.23 · globenewswire  |
12.10.23 · globenewswire |
20.09.23 · globenewswire |
09.08.23 · globenewswire |
07.07.23 · globenewswire |
Werte aus der Branche Telekommunikation
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +20,00 | |
| 48,84 | +13,58 | |
| 1,8600 | +12,73 | |
| 65,10 | +11,86 | |
| 14,200 | +9,23 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5100 | -8,12 | |
| 3,2100 | -8,29 | |
| 145,18 | -10,88 | |
| 2,0100 | -11,06 | |
| 19,310 | -32,76 |
Feedback
Nicht uninteressante, mE hochspekulative Aktie, wenn Sie 2 Jahre durchhalten und nicht von daytradern im Pennystockbereich kaputt gezockt wird.
Die wesentliche Nachricht der letzten Tage findet sich hier:
http://www.4-traders.com/news/Pacific-Therapeutics-Finalizes…
Kurzfassung: Lizenzabkommen zur Entwicklung einer im Mund auflöslichen Tablette zur Behebung von Erektionsstörungen. Diese werden angeblich von Patienten bevorzugt, Entwicklungszeit etwa 2 Jahre.
Die wesentliche Nachricht der letzten Tage findet sich hier:
http://www.4-traders.com/news/Pacific-Therapeutics-Finalizes…
Kurzfassung: Lizenzabkommen zur Entwicklung einer im Mund auflöslichen Tablette zur Behebung von Erektionsstörungen. Diese werden angeblich von Patienten bevorzugt, Entwicklungszeit etwa 2 Jahre.
einer im Mund auflöslichen Tablette zur Behebung von Erektionsstörungen
super, ein geniales Männerthema
super, ein geniales Männerthema
In anderen Foren findet man aber kein positives Feedback. Ausserdem wurde das Teil schon von SD bei 0,06 gezockt.
Wie gesagt, halte ich auch für eine hochspekulative Geschichte, aber wenn Sie es wirklich zur Marktreife bringen, könnte es interessant sein. Meine Altersvorsorge würde ich da aber nicht investieren...
Bin mal gespannt wie es weiter geht. Bin auch drin
Trading Spotlight
Es gibt immer wieder "Geschichten" die den "Machern" Geld bringen. Vorsicht!
Absolut, vor allem Geschichten von Stephen King oder JD Patterson. Die bringen diesen Machern besonders viel Geld ! :-)
Aber in Sache sehe ich es ähnlich, kann klappen, wenn das Papier nicht von Tradern kaputt gezockt wird. Hier sollte man nur Geld investieren, was man nicht braucht, und eventuell kann man in ein paar Jahren gut daran verdienen. Als Rentenvorsorge würde ich es aber nicht ins POrtfolio aufnehmen....
Aber in Sache sehe ich es ähnlich, kann klappen, wenn das Papier nicht von Tradern kaputt gezockt wird. Hier sollte man nur Geld investieren, was man nicht braucht, und eventuell kann man in ein paar Jahren gut daran verdienen. Als Rentenvorsorge würde ich es aber nicht ins POrtfolio aufnehmen....
Im Jahr 2011 der Gesamtmarkt für Medikamente zur Behandlung von Erektionsstörungen über $ 5 Milliarden . Pacific Therapeutics Ltd hat eine Lizenz auf eine mündliche Auflösen Technologie eines zugelassenen Medikament zur Behandlung der erektilen Dysfunktion abgeschlossen. Der Umsatz der Marktführer allein über $ 2 Milliarden im Jahr 2012. Die sublinguale Formulierung verbessert bestehende Medikamente zur Behandlung der erektilen Dysfunktion möglicherweise schneller zu wirken und mit weniger Nebenwirkungen . Als großen Pharmaunternehmen ihre Patente verlieren auf diese Medikamente eine riesige Chance für innovative Formulierungen von Medikamenten für ED entwickelt. Dies ist eine sehr aufregende Entwicklung für Pacific Therapeutics , da sie die Zeit, um für das Unternehmen das erste Produkt zu vermarkten und kann erheblich zu künftigen Einnahmen verkürzt . Mit Mitteln der jüngsten Privatplatzierung hat das Unternehmen auf dem bereits bedeutende Entwicklung der sublingualen Behandlung mit der Einleitung einer zulassungsrelevanten Studie Bioäquivalenz bauen . Dies ist der letzte Versuch , die vor dem Antrag auf Marktzulassung durchgeführt werden muss . Die Studie wird einschreiben 24 Personen und nur vier Monate dauern für die Fertigstellung. Mit der erfolgreichen Ergebnisse aus dieser Studie wird das Unternehmen beginnen den Antrag auf Marktzulassung .
Gibt es hier eigentlich auch irgendwann mal Zwischenberichte zum Sachstand der Arbeit oder müssen wir uns nun zwei Jahre auf unseren Hosenboden setzen und aufs Ungewisse warten ?
Antwort auf Beitrag Nr.: 46.566.929 von Kliso am 05.03.14 10:22:08kamen doch news gestern.
Antwort auf Beitrag Nr.: 46.620.279 von ultrawuffsn am 13.03.14 10:02:27Allowance by European Patent Office, of Patent For PTL-202, a Treatment for Idiopathic Pulmonary Fibrosis, a $1.1 Billion Opportunity
C.PT | 21 hours ago
(via Thenewswire.ca)
VANCOUVER, BC, Canada / TNW-ACCESSWIRE / March 12, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (Frankfurt: 1P3) (the "Company") Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF), (IPF Coalition). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.
Pacific Therapeutics Ltd. lead drug candidate for fibrosis (progressive scarring of the organ), PTL-202 is a combination of Pentoxifylline an FDA approved drug and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant.
The Company is pleased to announce that the European Patent Office has issued an official letter stating that it intends to allow the application for the Company's patent COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS. This patent covers the composition and use of the combination of drugs used in the Company's lead product for treatment of IPF and includes claims for the use of the combination to treat liver fibrosis, kidney fibrosis, uterine fibrosis and peripheral arterial disease.
"It's estimated that 45 % of all deaths are related to fibrotic changes" World Health Organization Feb, 2008.
In addition to the $1.1 billion IPF market opportunity, PTL-202 may be effective as a treatment for Liver Cirrhosis a $1.56 billion global market opportunity in 2010, that is expected to grow to $2.03 billion by 2017 (Global Data, Feb, 2011). "This growth is primarily attributed to the increasing prevalence of Liver Cirrhosis due to increase in alcoholic liver disease, nonalcoholic steatohepatitis (NASH) and the large group of patients who were originally infected with hepatitis virus, who will be entering their third decade of chronic liver infection" (Global Data, Feb, 2011).
ABOUT PACIFIC THERAPEUTICS LTD.
The Company's lead programs focus on erectile dysfunction and diseases of excessive scarring (fibrosis). The Company's strategy includes reformulating approved drugs to increase efficacy and patient compliance, while reducing side effects, as well as completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.
.
In 2011 the total market for drugs to treat erectile dysfunction ("ED") exceeded $5 billion. Pacific Therapeutics Ltd. has finalized a license to an oral dissolving technology ("sublingual formulation") of an approved drug to treat erectile dysfunction (ED).
Sales of the market leader alone exceeded $1.9 billion in 2011. The sublingual formulation improves on existing drugs for erectile dysfunction potentially acting faster and with fewer side effects. As large pharmaceutical companies lose their patents on these drugs the opportunity has developed for innovative formulations of drugs for ED. This is a very exciting development for Pacific Therapeutics Ltd. as it shortens the time to market for the Company's first product and may add significantly to future revenues.
The Company plans to build on the already significant development of the sublingual treatment with the initiation of a pivotal Bioequivalence trial. The trail design calls for the enrolment of 24 individuals and is planned take only 4 months for completion. With successful results from this trial the Company will begin the application for marketing approval.
For further information visit our website at www.pacifictherapeutics.com or email us at doug.unwin@pacifictherapeutics.com
Douglas H. Unwin, CEO & President
(604) 738-1049
doug.unwin@pacifictherapeutics.com
FORWARD LOOKING STATEMENTS
Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.
Copyright (c) 2014 TheNewswire - All rights reserved.
TheNewsWire
March 12, 2014 - 8:30 AM EDT
Read more at http://www.stockhouse.com/news/press-releases/2014/03/12/all…
C.PT | 21 hours ago
(via Thenewswire.ca)
VANCOUVER, BC, Canada / TNW-ACCESSWIRE / March 12, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (Frankfurt: 1P3) (the "Company") Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF), (IPF Coalition). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.
Pacific Therapeutics Ltd. lead drug candidate for fibrosis (progressive scarring of the organ), PTL-202 is a combination of Pentoxifylline an FDA approved drug and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant.
The Company is pleased to announce that the European Patent Office has issued an official letter stating that it intends to allow the application for the Company's patent COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS. This patent covers the composition and use of the combination of drugs used in the Company's lead product for treatment of IPF and includes claims for the use of the combination to treat liver fibrosis, kidney fibrosis, uterine fibrosis and peripheral arterial disease.
"It's estimated that 45 % of all deaths are related to fibrotic changes" World Health Organization Feb, 2008.
In addition to the $1.1 billion IPF market opportunity, PTL-202 may be effective as a treatment for Liver Cirrhosis a $1.56 billion global market opportunity in 2010, that is expected to grow to $2.03 billion by 2017 (Global Data, Feb, 2011). "This growth is primarily attributed to the increasing prevalence of Liver Cirrhosis due to increase in alcoholic liver disease, nonalcoholic steatohepatitis (NASH) and the large group of patients who were originally infected with hepatitis virus, who will be entering their third decade of chronic liver infection" (Global Data, Feb, 2011).
ABOUT PACIFIC THERAPEUTICS LTD.
The Company's lead programs focus on erectile dysfunction and diseases of excessive scarring (fibrosis). The Company's strategy includes reformulating approved drugs to increase efficacy and patient compliance, while reducing side effects, as well as completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.
.
In 2011 the total market for drugs to treat erectile dysfunction ("ED") exceeded $5 billion. Pacific Therapeutics Ltd. has finalized a license to an oral dissolving technology ("sublingual formulation") of an approved drug to treat erectile dysfunction (ED).
Sales of the market leader alone exceeded $1.9 billion in 2011. The sublingual formulation improves on existing drugs for erectile dysfunction potentially acting faster and with fewer side effects. As large pharmaceutical companies lose their patents on these drugs the opportunity has developed for innovative formulations of drugs for ED. This is a very exciting development for Pacific Therapeutics Ltd. as it shortens the time to market for the Company's first product and may add significantly to future revenues.
The Company plans to build on the already significant development of the sublingual treatment with the initiation of a pivotal Bioequivalence trial. The trail design calls for the enrolment of 24 individuals and is planned take only 4 months for completion. With successful results from this trial the Company will begin the application for marketing approval.
For further information visit our website at www.pacifictherapeutics.com or email us at doug.unwin@pacifictherapeutics.com
Douglas H. Unwin, CEO & President
(604) 738-1049
doug.unwin@pacifictherapeutics.com
FORWARD LOOKING STATEMENTS
Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.
Copyright (c) 2014 TheNewswire - All rights reserved.
TheNewsWire
March 12, 2014 - 8:30 AM EDT
Read more at http://www.stockhouse.com/news/press-releases/2014/03/12/all…
Antwort auf Beitrag Nr.: 46.620.659 von ultrawuffsn am 13.03.14 10:56:42da hst sich einer die 0,050 in frankfurt geschnappt.
denke hier gehts jetzt bald steil hoch.werde mich heut drüben auf die lauer legen.
denke hier gehts jetzt bald steil hoch.werde mich heut drüben auf die lauer legen.
Antwort auf Beitrag Nr.: 46.620.659 von ultrawuffsn am 13.03.14 10:56:42Last Traded: March 12, 2014 07:58 Transaction Volume: 27,000
Open: $0.085 Previous Close: $0.08
Bid: $0.065 Ask: $0.085
Bid Size: 10,000 Ask Size: 30,000
Market Cap: $2.3m Shares Out: 26.6m
PE Ratio: N/A Dividend Yield: N/A
MK nur 2 mio.
Open: $0.085 Previous Close: $0.08
Bid: $0.065 Ask: $0.085
Bid Size: 10,000 Ask Size: 30,000
Market Cap: $2.3m Shares Out: 26.6m
PE Ratio: N/A Dividend Yield: N/A
MK nur 2 mio.
Antwort auf Beitrag Nr.: 46.620.705 von ultrawuffsn am 13.03.14 11:00:370,047/0,055 frankfurt,dürfte bald starten nach der news gestern.werde mir auch welche holen.aber erst mal schauen was can macht heute.wenn nix passiert kann man in frankfurt paar abstauben.
Antwort auf Beitrag Nr.: 46.621.401 von ultrawuffsn am 13.03.14 12:32:29wenn die masse draufspringt ist es zu spät deshalb jetzt paar teile holen und warten.die läuft demnächst an.unten sind wir.seit monaten auf diesem level.
Das hoffe ich doch ^^
Ich bin vor einiger Zeit (als die Aktie in DE angepriesen wurde) auf den Zuf aufgesprungen und habe daher nen relativ hohen Einstiegskurs von 0,08 €...
War damals nen bisschen unüberlegt von mir, so schnell zu handeln, die Aktie war total im Hype, ist bis auf 0,14 € hoch und dann ebenso schnell eingebrochen ;-)
Aber nachdem nun die News rauskam, müssen wir mal abwarten, was in CAN so passiert. Das Volumen ist halt sehr sehr gering, das muss natürlich anziehen und evtl. muss die Nachricht auch erstmal das entsprechende "Publikum" erreichen, bevor sich vllt ein neuer Hype aufbaut !
Naja, selber Spiel wie immer: Abwarten und Tee trinken ;-)
Ich bin vor einiger Zeit (als die Aktie in DE angepriesen wurde) auf den Zuf aufgesprungen und habe daher nen relativ hohen Einstiegskurs von 0,08 €...
War damals nen bisschen unüberlegt von mir, so schnell zu handeln, die Aktie war total im Hype, ist bis auf 0,14 € hoch und dann ebenso schnell eingebrochen ;-)
Aber nachdem nun die News rauskam, müssen wir mal abwarten, was in CAN so passiert. Das Volumen ist halt sehr sehr gering, das muss natürlich anziehen und evtl. muss die Nachricht auch erstmal das entsprechende "Publikum" erreichen, bevor sich vllt ein neuer Hype aufbaut !
Naja, selber Spiel wie immer: Abwarten und Tee trinken ;-)
United States Securities and Exchange Commission Declares Pacific Therapeutics Registration Statement Effective
(via Thenewswire.ca)
VANCOUVER, BC, Canada / TNW-ACCESSWIRE / March 18, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (Frankfurt: 1P3) (the "Company") is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on erectile dysfunction and diseases of excessive scarring (fibrosis) which are $1 billion plus market opportunities.
The Company is pleased to announce that the United States Securities and Exchange Commission (SEC) has issued an order in the matter of Pacific Therapeutics Ltd. "declaring registration effective pursuant to section 12(g) of the securities exchange act of 1934 as amended".
Doug Unwin CEO and President of the Company stated "having our 20F registration statement declared effective by the SEC is the attainment of yet another of our stated milestones and is one step further towards our goal of obtaining a quotation of the Company's shares in the United States".
ABOUT PACIFIC THERAPEUTICS LTD.
The Company's strategy includes reformulating approved drugs to increase efficacy and patient compliance, while reducing side effects, as well as completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.
Pacific Therapeutics Ltd. lead drug candidate for fibrosis (progressive scarring of the organ), PTL-202 is a combination of Pentoxifylline an FDA approved drug and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant. The Company has completed an initial clinical trial of the combination with positive results. "It's estimated that 45 % of all deaths are related to fibrotic changes" World Health Organization Feb, 2008.
Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF), (IPF Coalition). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.
In 2011 the total market for drugs to treat erectile dysfunction ("ED") exceeded $5 billion. Pacific Therapeutics Ltd. has finalized a license to an oral dissolving technology ("sublingual formulation") of an approved drug to treat erectile dysfunction (ED).
Sales of the market leader alone exceeded $1.9 billion in 2011. The sublingual formulation may improve on existing drugs for erectile dysfunction potentially acting faster and with fewer side effects. As large pharmaceutical companies lose their patents on these drugs the opportunity has developed for innovative formulations of drugs for ED. This is a very exciting development for Pacific Therapeutics Ltd. as it shortens the time to market for the Company's first product and may add significantly to future revenues.
The Company plans to build on the already significant development of the sublingual treatment with the initiation of a pivotal Bioequivalence trial. With successful results from this trial the Company will begin the application for marketing approval.
For further information visit our website at www.pacifictherapeutics.com or email us at doug.unwin@pacifictherapeutics.com
Douglas H. Unwin, CEO & President
(604) 738-1049
doug.unwin@pacifictherapeutics.com
FORWARD LOOKING STATEMENTS
Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.
Copyright (c) 2014 TheNewswire - All rights reserved.
(via Thenewswire.ca)
VANCOUVER, BC, Canada / TNW-ACCESSWIRE / March 18, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (Frankfurt: 1P3) (the "Company") is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on erectile dysfunction and diseases of excessive scarring (fibrosis) which are $1 billion plus market opportunities.
The Company is pleased to announce that the United States Securities and Exchange Commission (SEC) has issued an order in the matter of Pacific Therapeutics Ltd. "declaring registration effective pursuant to section 12(g) of the securities exchange act of 1934 as amended".
Doug Unwin CEO and President of the Company stated "having our 20F registration statement declared effective by the SEC is the attainment of yet another of our stated milestones and is one step further towards our goal of obtaining a quotation of the Company's shares in the United States".
ABOUT PACIFIC THERAPEUTICS LTD.
The Company's strategy includes reformulating approved drugs to increase efficacy and patient compliance, while reducing side effects, as well as completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.
Pacific Therapeutics Ltd. lead drug candidate for fibrosis (progressive scarring of the organ), PTL-202 is a combination of Pentoxifylline an FDA approved drug and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant. The Company has completed an initial clinical trial of the combination with positive results. "It's estimated that 45 % of all deaths are related to fibrotic changes" World Health Organization Feb, 2008.
Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF), (IPF Coalition). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.
In 2011 the total market for drugs to treat erectile dysfunction ("ED") exceeded $5 billion. Pacific Therapeutics Ltd. has finalized a license to an oral dissolving technology ("sublingual formulation") of an approved drug to treat erectile dysfunction (ED).
Sales of the market leader alone exceeded $1.9 billion in 2011. The sublingual formulation may improve on existing drugs for erectile dysfunction potentially acting faster and with fewer side effects. As large pharmaceutical companies lose their patents on these drugs the opportunity has developed for innovative formulations of drugs for ED. This is a very exciting development for Pacific Therapeutics Ltd. as it shortens the time to market for the Company's first product and may add significantly to future revenues.
The Company plans to build on the already significant development of the sublingual treatment with the initiation of a pivotal Bioequivalence trial. With successful results from this trial the Company will begin the application for marketing approval.
For further information visit our website at www.pacifictherapeutics.com or email us at doug.unwin@pacifictherapeutics.com
Douglas H. Unwin, CEO & President
(604) 738-1049
doug.unwin@pacifictherapeutics.com
FORWARD LOOKING STATEMENTS
Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.
Copyright (c) 2014 TheNewswire - All rights reserved.
Possitiv - Das Unternehmen erweitert sein Handlungsumfeld
Doug Unwin CEO und Präsident des Unternehmens, sagte: " mit unserer Aktien in den Vereinigten Staaten notiert ist das Erreichen eines weiteren der von uns angegebenen Meilensteine und ist einen Schritt weiter in Richtung unseres Ziels die Sichtbarkeit des Unternehmens in der US- Aktienmärkte sowie die Erhöhung der Liquidität der Aktien der Gesellschaft . "
Doug Unwin CEO und Präsident des Unternehmens, sagte: " mit unserer Aktien in den Vereinigten Staaten notiert ist das Erreichen eines weiteren der von uns angegebenen Meilensteine und ist einen Schritt weiter in Richtung unseres Ziels die Sichtbarkeit des Unternehmens in der US- Aktienmärkte sowie die Erhöhung der Liquidität der Aktien der Gesellschaft . "
Gibt es Erwartungen für News?
Der Kurs spingt ja ganz schön rum.
Der Kurs spingt ja ganz schön rum.
Tote Hose hier... was neues 
Antwort auf Beitrag Nr.: 47.547.100 von Jay-c am 18.08.14 17:20:49ich habe auch teuer gekauft und warte eigentlich das sich endlich wtwas tut aber ob das jemals passiert weiß ich nicht
Haha deswegen ist der Kurz 44% nach oben gegangen... 
Ich habe auch überlegt.. ich meine paar hundert € sören mich nicht wenn sie da jahre lang bleiben oder sogar verschwinden..
Ich habe auch überlegt.. ich meine paar hundert € sören mich nicht wenn sie da jahre lang bleiben oder sogar verschwinden..
Antwort auf Beitrag Nr.: 47.581.600 von Jay-c am 22.08.14 08:02:55
warte bis sie eine dividende bezahlen wird sich ausgehen solange lebe ich vielleicht noch
warte bis sie eine dividende bezahlen wird sich ausgehen solange lebe ich vielleicht noch
Denke hier wird sich Monate nichts tun...
Erst wenn der Launch erreicht ist bzw. bei den Medikamenten Phase 3 oder 4 wird es spannend. Dann KANN es nach oben schießen bzw. wenn die Phasen nicht erreicht werden oder die klinischen Studien negativ sind, ist das Investment wohl verloren.
http://pacifictherapeutics.com/pipeline_technology/product_p…
Erst wenn der Launch erreicht ist bzw. bei den Medikamenten Phase 3 oder 4 wird es spannend. Dann KANN es nach oben schießen bzw. wenn die Phasen nicht erreicht werden oder die klinischen Studien negativ sind, ist das Investment wohl verloren.
http://pacifictherapeutics.com/pipeline_technology/product_p…
Antwort auf Beitrag Nr.: 47.609.766 von Werterherr am 26.08.14 11:27:39Ja stimmt.. aber wie du sagst erst wenn Phase 3 oder 4 kommt wird es spannend. Doch da steht der kurz nicht mehr bei 0,03 sondern bei 0,30.
Ruhe vor dem Sturm?
Hier ist es ja schon extrem lange Ruhig.
Gibt es inzwischen wieder mal News?
Ich meine mehr als Absichtserklärungen und wenn / dann's?
Antwort auf Beitrag Nr.: 49.496.747 von Shaples am 04.04.15 20:44:44Pacific wurde sosehr als Aufsteiger gepriesen, aber es bewegt sich kaum was-- doch bei Medikamenten sollte es doch schneller gehen. Wer kann Neues zu dieser Aktie sagen ?
Naja, das hier sind schon sehr interessante "News", vom 21. Mai, wenn es stimmt
http://pacifictherapeutics.com/investor/news/pacific-therape…
Danach BEABSICHTIGT PT den Verkauf seiner beiden wesentlichen Produkte an die Firma "Pilotage South Corp. of Wyoming". Dafür sollen PT 15 Mio Anteile erhalten, außerdem werden jährlich 50.000 $ gezahlt, bis der Deal abgeschlossen ist.
Beunruhigend eher der Nebensatz, dass Pilotage auch 500.000 $ SCHULDEN übernimmt, so dass führende Mitarbeiter von PT bezahlt werden können.
http://pacifictherapeutics.com/investor/news/pacific-therape…
Danach BEABSICHTIGT PT den Verkauf seiner beiden wesentlichen Produkte an die Firma "Pilotage South Corp. of Wyoming". Dafür sollen PT 15 Mio Anteile erhalten, außerdem werden jährlich 50.000 $ gezahlt, bis der Deal abgeschlossen ist.
Beunruhigend eher der Nebensatz, dass Pilotage auch 500.000 $ SCHULDEN übernimmt, so dass führende Mitarbeiter von PT bezahlt werden können.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,75 | |
| 0,00 | |
| -11,55 | |
| -4,92 | |
| +2,15 | |
| +0,32 | |
| -100,00 | |
| -4,35 | |
| +9.900,00 | |
| +7,14 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 240 | ||
| 90 | ||
| 86 | ||
| 86 | ||
| 60 | ||
| 55 | ||
| 53 | ||
| 47 | ||
| 41 | ||
| 33 |
